More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$8.05B
EPS
-2.91
P/E ratio
--
Price to sales
2.07
Dividend yield
--
Beta
1.630784
Previous close
$168.92
Today's open
$168.01
Day's range
$159.54 - $170.17
52 week range
$91.86 - $228.88
show more
CEO
James C. Foster
Employees
20100
Headquarters
Wilmington, MA
Exchange
New York Stock Exchange
Shares outstanding
49227800
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks Investment Research • 10 hours ago

Investing in Charles River (CRL)? Don't Miss Assessing Its International Revenue Trends
Evaluate Charles River's (CRL) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Zacks Investment Research • Feb 23, 2026

Charles River forecasts upbeat 2026 profit on improved demand for drug development services
Contract drug developer Charles River Laboratories on Wednesday forecast annual profit above Wall Street estimates, betting on an improvement in demand for its drug discovery and development services from biotech clients.
Reuters • Feb 18, 2026

Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
Charles River Laboratories International, Inc. (CRL) Q4 2025 Earnings Call Transcript
Seeking Alpha • Feb 18, 2026

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance.
Business Wire • Feb 18, 2026

Charles River Laboratories (CRL) Q4 Earnings and Revenues Surpass Estimates
Charles River Laboratories (CRL) came out with quarterly earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.33 per share. This compares to earnings of $2.66 per share a year ago.
Zacks Investment Research • Feb 18, 2026

CRL Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise
Charles River tops Q4 earnings and revenue estimates as margins expand, but shares dip, and organic growth declines across all segments.
Zacks Investment Research • Feb 18, 2026

Here's What Key Metrics Tell Us About Charles River (CRL) Q4 Earnings
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Feb 18, 2026

Charles River Laboratories Announces Executive Appointments
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Executive Appointments.
Business Wire • Feb 18, 2026

Charles River Laboratories Q4 Review: Approaching A Bottom
Charles River Laboratories Q4 Review: Approaching A Bottom
Seeking Alpha • Feb 18, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Charles River Laboratories International Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.